Better Health for All

Performance One AG's primary health-related offerings, as described in the articles, are the mental health platforms couch:now and harmony.

These platforms provide psychological support, self-help for issues like couples counseling, loneliness, and burnout, and have been scientifically proven to reduce stress. This indicates that a significant portion of the company's health-related offerings deliver substantial health benefits, with health impact central to its strategy. The company has made significant investments in these e-health initiatives and AI co-products, including receiving research grants from the German Federal Ministry of Education and Research (BMBF). The mental health platforms are marketed as digital prevention applications, but the company's overall focus is not predominantly on prevention. While the company aims for health insurance reimbursement and corporate provision, currently only around 2,500 self-paying members use the platform, which is offered at monthly (EUR 19) or annual (EUR 69) subscriptions or as one-time purchases (EUR 159). This pricing structure, without widespread reimbursement, limits accessibility. The company's vision is for universal mental health access, but its current reach to vulnerable populations is limited to those who can afford the subscriptions or are covered by specific health insurers/employers. The couch:now platform was created during the Corona pandemic, indicating a reactive response to a health crisis. Addiction counseling is expected to follow soon on the platform, but is not yet available. The company has recruited leading psychologists to create content for couch:now and developed it in cooperation with universities, doctors, and therapists, and in 2023, the effectiveness of couch:now in reducing stress was scientifically proven.

Fair Money & Economic Opportunity

PERFORMANCE ONE AG is a medical technology company focused on cancer treatment. The provided articles discuss general topics related to financial inclusion, fintech, and regulatory trends in the financial services sector. None of the articles contain any specific, concrete data points, actions, or policies pertaining to PERFORMANCE ONE AG's involvement in lending, financial services, or any activities relevant to the 'Fair Money & Economic Opportunity' value.

Therefore, there is no evidence to score any of the KPIs for this company against this value.

No War, No Weapons

The provided articles focus exclusively on PERFORMANCE ONE AG's (formerly MagForce AG) NanoTherm therapy for prostate cancer, detailing FDA investigational device exemption (IDE) approvals and clinical trial progress.

No information or data points relevant to arms manufacturing, military contracts, conflict facilitation, peacebuilding initiatives, or any other metrics related to the 'No War, No Weapons' ethical value are present in the articles. Therefore, all KPIs are omitted due to a lack of specific evidence.

Planet-Friendly Business

The company's SBTi targets were validated in May 2024.

These targets include a 42% reduction in Scope 1, 2, and 3 emissions by 2030 from a 2022 baseline, and a 90% reduction in Scope 1, 2, and 3 emissions by 2045 from a 2022 baseline. The company has a stated net-zero carbon target year of 2045.

Safe & Smart Tech

The company's NanoTherm therapy has received EMA approval and a CE mark in Europe for brain cancer treatment.

Additionally, the company received Investigational Device Exemption (IDE) approval from the US FDA for a pivotal clinical trial for prostate cancer and updated preclinical study data to meet FDA standards. These actions demonstrate good compliance with applicable medical device regulations in major markets.